Investment Bank Initiates Coverage of Caliper with Outperform Rating

Wedbush also placed a 12-month price target of $9 on Caliper's shares, saying that "new product traction in next-generation sequencing sample preparation as well as greater adoption of the company's products in molecular diagnostics can drive upside to consensus estimates."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories